New therapeutic system for tumors like Non-Hodgkin lymphoma: Immunotherapy Kumar Jeetendra | April 26, 2020 Today, immunotherapy is one of the most encouraging treatment for malignant growth patients. In contrast to radio-or chemo-treatments, immunotherapy intends to “switch on” the patient’s own resistant framework to assault and wipe out the tumor. In any case, tumors, including NHL, frequently change to make themselves undetectable to the invulnerable framework or even adventure cooperations …
MD Anderson and Sanofi work together to quicken improvement of imaginative malignant growth treatments Kumar Jeetendra | July 15, 2020 At the University of Texas MD Anderson Cancer Center and Sanofi currently declared a last-minute tactical alliance to hasten the evolution of investigational treatments, for example immune and targeted treatments, for patients with cancer. “Our goal is to enhance the results for patients using a selection of difficult-to-treat cancers, that will be best achieved via …
New initiative identifies key parameters Inherent effective anti-tumor immunity Kumar Jeetendra | October 10, 2020 Neoantigens, tiny markers that arise from cancer mutations, flag cells as cancerous and could be the key to unlocking a new generation of immunotherapies. Targeting the”right” neoantigens – at a cancer vaccine or a cell treatment – has the promise to eliminate a patient’s cancer with minimal side effects. But countless mutations can exist in …
Stewart Kay joins Adaptate Biotherapeutics as Chief Business Officer Kumar Jeetendra | October 28, 2020 In this new role, Stewart will work as part of the Executive staff to drive Adaptate’s Business and Corporate Development activities. Stewart Kay, CBO, Adaptate Biotherapeutics Adaptate is developing a range of therapeutic antibodies that recognize drug targets and have the potential to modulate the activity of gamma delta T cells. Gamma delta T cells …
Drug used to control pulse may improve malignant growth patients’ reaction to immunotherapy Kumar Jeetendra | November 1, 2020 The exact same biochemical triggers which spur a”flight or fight” reaction once we encounter threats may help tumor cells to thrive. A group of researchers from Roswell Park Comprehensive Cancer Center is looking at ways to interrupt that dynamic so that cancer therapies can be effective. Their latest work, published today in Clinical Cancer Research, …
Dexamethasone use could reduce immune checkpoint inhibitor viability in glioblastoma patients Kumar Jeetendra | November 25, 2020 Bottom Line: One of patients with glioblastoma getting an immune checkpoint inhibitor, people who obtained the corticosteroid dexamethasone at baseline for cerebral edema had significantly worse overall survival. Journal Where the Study was Released: Clinical Cancer Research, a journal of the American Association for Cancer Research Author: David A. Reardon, MD, clinical director of the …
Second-generation double antibody shields from SARS-CoV-2 and its tried variations Kumar Jeetendra | January 25, 2021 Additionally, it prevents the virus from mutating to resist the treatment . Antibody-based immunotherapy was already proven to work against COVID-19 but faces two chief obstacles: it requires to work against the circulating viral variants; it has to avoid formation of new variants, that can rapidly ensue using a mechanism similar to that leading to …
Novel hydrogel gradually delivers RNA nanovaccines to shrivel tumors Kumar Jeetendra | February 18, 2021 Messenger RNA (mRNA) vaccines to stop COVID-19 have made headlines around the world recently, but scientists also have been working on mRNA vaccines to treat or prevent other diseases, including some forms of cancer. Cancer immunotherapy vaccines operate similarly to mRNA vaccines for COVID-19, except they trigger the immune system to attack tumors rather than …
Bacteria residing within inside tumor cells can support malignant growth immunotherapy Kumar Jeetendra | March 22, 2021 Cancer immunotherapy may get a boost from an unexpected direction: bacteria residing within tumor cells. The study may also help clarify the connection between immunotherapy and the intestine microbiome, describing the findings of earlier research that the microbiome impacts the success of immunotherapy. Immunotherapy remedies of the last decade or so have dramatically improved healing …
UCL researchers distinguish new immunotherapy to battle hepatitis B infection Kumar Jeetendra | May 15, 2021 Researchers at UCL have identified a new immunotherapy to fight the hepatitis B virus (HBV), the most frequent cause of liver cancer in the world. The pioneering study used immune cells isolated directly from patient liver and tumour tissue, to demonstrate that targeting acyl-CoA:cholesterol acyltransferase (ACAT), an enzyme which helps to manage cholesterol levels in …
Researchers develop experimental direct-acting antiviral treatment to treat COVID-19 Kumar Jeetendra | May 18, 2021 An international team of scientists from the Menzies Health Institute Queensland (MHIQ) at Griffith University and from City of Hope, a research and treatment center for cancer, diabetes and other life-threatening diseases in the U.S., have developed an experimental direct-acting antiviral therapy to treat COVID-19. Conventional antivirals reduce symptoms and help people recover earlier. Examples …
Weight-based dosing procedure may influence immunotherapy results, shows study Kumar Jeetendra | June 15, 2021 Overweight cancer patients receiving immunotherapy treatments live more than twice as long as lighter patients, but only when dosing is weight-based, according to a study by cancer researchers at UT Southwestern Medical Center. The findings, published in the Journal for ImmunoTherapy of Cancer, run counter to current practice trends, which favor fixed dosing, in which …
